台股 » 個股 » 生展 » 籌碼相關 » 券商分點績效 » 券商分點個股進出

生展

(8279)
  • 股價
    150.0
  • 漲跌
    ▼3.0
  • 漲幅
    -1.96%
  • 成交量
    3
  • 產業
    上櫃 生技醫療類股▼0.76%
  • 68人加入追蹤

    立即追蹤

  • 本地時間:13:30

     
生展 (8279)籌碼相關-兆豐-松德 券商分點個股進出
券商分點績效/獲利分析

透過統計各券商分點在長期買賣某個股的操作績效,來找出真正獲利的贏家所在券商分點,進而追蹤此贏家所操作的股票與軌跡。

兆豐-松德 券商分點個股進出

日期買進張數買進均價賣出張數賣出均價收盤價買賣超60日均量成交佔比 大量交易提示
2023/03/1000.001170.50171.00-165-1.53%
2023/03/091174.5000.00173.001651.53%
2023/03/0600.001181.50180.00-160-1.67%
2022/12/1500.005151.00150.50-560-8.23%
2022/12/0700.006151.67153.00-659-10.01%
2022/12/0600.004150.25149.50-461-6.49%
2022/12/011141.001143.50145.000620.00%
2022/11/222139.0000.00138.502742.68%
2022/11/176145.0000.00149.506748.03%
2022/11/112134.5000.00136.002812.47%
2022/11/071138.5000.00139.501911.09%
2022/10/2600.001136.00142.00-1100-1.00%
2022/10/2500.002137.00136.50-2100-1.99%
2022/10/2400.001139.50139.50-1101-0.98%
2022/10/2100.002142.50145.00-2101-1.97%
2022/10/1300.001140.50143.00-1104-0.96%
2022/09/2800.003144.00141.50-3103-2.91%
2022/09/0800.005173.70172.00-594-5.28%
2022/09/0200.006175.00176.00-693-6.45%
2022/08/311177.5000.00175.001951.05%
2022/08/293178.0000.00178.003913.30%
2022/08/263175.0000.00174.503893.37%
2022/08/2300.002171.00171.00-283-2.38%
2022/08/222174.5000.00170.002812.44%
2022/08/191163.001164.00169.000770.00%
2022/08/186159.6700.00160.006748.10%
2022/08/1500.0010154.00154.00-1065-15.20%
2022/08/112152.0000.00150.002593.34%
2022/08/109144.1700.00146.0095616.00%
2022/08/0912135.6700.00137.00125023.87%
2021/07/0600.000.1108.50109.00-0.140-0.23%
2021/06/2900.000.6110.00111.00-0.641-1.44%
2021/06/2300.001106.00105.00-139-2.51%
2021/06/1700.001107.00106.50-137-2.64%
2021/06/112105.7500.00106.002385.14%
2020/11/2700.001112.50112.50-140-2.47%
2020/11/2500.001112.50112.50-140-2.49%
2020/11/0200.002110.75110.50-298-2.02%
2020/10/0600.001112.00112.00-1117-0.85%
2020/09/1100.002112.50112.50-2131-1.52%
2020/09/103116.6700.00113.5031302.29%
2020/08/2700.001128.00128.00-1125-0.79%
2020/08/261127.0000.00126.5011250.80%
2020/08/252128.7500.00127.5021241.60%
2020/08/201126.0000.00125.5011210.82%
2020/08/191133.501132.00135.0001150.00%
2020/08/1700.001130.00129.50-1108-0.92%
2020/08/101128.0000.00129.001961.04%
2020/08/071126.5000.00130.001921.08%
2020/08/061122.501127.50127.500810.00%
2020/07/2700.001115.50117.00-177-1.29%
2020/07/2300.002117.00117.50-279-2.53%
2020/07/2100.001116.00116.00-177-1.28%
2020/07/2000.002115.50116.00-277-2.60%
2020/07/1500.001115.00115.00-172-1.38%
2020/07/1400.001113.50113.50-172-1.38%
2020/07/0900.001114.50115.00-167-1.48%
2020/07/0800.001114.00114.00-166-1.50%
2020/06/0800.001117.00117.00-174-1.34%
2020/05/1400.004106.50107.50-495-4.19%
2020/03/13190.40192.8093.900800.00%
2020/03/122101.0000.00100.002782.56%
2020/03/101109.0000.00110.001741.35%
2020/02/1400.003110.00109.50-364-4.65%
2020/02/063109.0000.00109.003674.46%
2020/01/311112.5000.00112.001611.62%
2020/01/1000.001115.00115.50-163-1.58%
2020/01/0900.002115.00116.50-263-3.17%
2019/12/2700.005118.00118.50-568-7.25%
2019/12/183120.3300.00119.503684.39%
2019/12/101116.0000.00116.501691.44%
2019/12/025118.0000.00118.505677.40%
2019/11/211115.0000.00116.501611.62%
2019/11/141116.001114.00114.000590.00%
2019/11/122116.502116.00116.000590.00%
2019/10/291125.5000.00124.501691.44%
2019/10/071129.0000.00130.501971.03%
2019/10/041133.5000.00130.0011000.99%
2019/09/201136.0000.00134.0011160.86%
2019/09/041143.0000.00143.5011140.88%
2019/08/2900.001147.00148.00-1113-0.88%
2019/08/1600.001138.00137.50-1105-0.95%
2019/08/151132.0000.00137.0011040.95%
2019/08/121139.0000.00139.5011020.98%
2019/07/302147.2500.00151.002922.15%
2019/07/2900.001160.00159.50-186-1.16%
2019/07/223150.1700.00154.003813.68%
2019/06/0300.001118.00119.00-159-1.68%
2019/05/1600.001119.50120.00-167-1.49%
2019/05/1500.001121.00121.00-167-1.49%
2019/05/141116.5000.00119.001661.50%
2019/05/101124.0000.00124.001661.51%
2019/04/2200.001120.50120.50-158-1.71%
2019/03/111125.0000.00123.501392.55%
2019/03/081116.5000.00120.001362.72%
2018/04/231178.503180.33172.00-2364-0.55%
2018/04/202170.5000.00173.0023420.58%
〈國光生展望〉子公司安特羅腸病毒三期臨床入尾聲 明年展開IPOAnue鉅亨-2023/12/26
〈國光生展望〉流感疫苗申請巴西藥證+破傷風切新市場 外銷業績拚成長Anue鉅亨-2023/12/26
〈聯合再生展望〉洪傳獻:TOPCon技術明年成主流 獲利表現佳Anue鉅亨-2023/10/16
生展 相關文章